Galux Named to 2026 CB Insights’ 50 Most Promising Digital Health Startups

Galux has been named to CB Insights’ eighth annual Digital Health 50, which recognizes 50 promising digital health startups in the world, as one of five startups in the Drug Discovery & Development category.

“AI is beginning to change not just how healthcare organizations operate, but how they actually deliver care,” said Ellen Knapp, Lead Healthcare Analyst at CB Insights. “This year’s Digital Health 50 winners are finding new ways to extend clinicians’ reach, simplify how patients access treatment, and deliver more continuous care for complex conditions.”

The list primarily includes companies using AI to reshape care delivery, streamline healthcare operations, and improve patients’ access to treatment. CB Insights research team picked winning companies based on CB Insights datasets, including deal activity, industry partnerships, team strength, investor strength, employee headcount, and proprietary metrics.

Galux develops GaluxDesign, its proprietary AI protein design platform for creating novel proteins and antibodies de novo. The platform is designed to build therapeutic properties into molecules from the outset, generating high-quality candidates with precision rather than at scale.

Galux has established itself among the leading groups in de novo antibody design, combining advanced AI design capabilities with strong experimental validation. Across nine shared therapeutic targets with publicly reported results from other AI antibody design platforms, Galux de novo designed and experimentally validated antibodies against eight targets, achieving the highest target-level success among the platforms compared. The company is now extending its technology to increasingly challenging targets, such as GPCRs, and more complex therapeutic modalities.

“As global interest in AI-driven drug design continues to grow, the ability to precisely design differentiated molecules with the properties required for therapeutic development is becoming a key competitive advantage,” said Taeyong Park, CEO of Galux. “We are pleased to see the capabilities Galux has built in precision protein design, and our ability to translate them toward real drug development, recognized on a global stage.”

Galux is applying its technology through collaborations with various pharmaceutical partners including AstraZeneca, while advancing its own therapeutic pipeline. Earlier this year, the company was also named to the Forbes Asia 100 to Watch 2026 in the Biotechnology & Healthcare category.

Quick facts on the 2026 Digital Health 50:

  • $3.6B in equity funding raised over time, including $2B in 2026 so far

  • 91 partnerships announced since 2025, including with industry leaders like Mayo Clinic, Merck and Siemens Healthineers

  • Employ 6,000+ people, with a median headcount of 84 across the cohort

  • Rank among the top 10% of private companies globally for overall health and growth potential (by CB Insights’ Mosaic Score)

About CB Insights

CB Insights spots winners in emerging tech. Since 2009, it has ranked and rated the private companies reshaping their industries, drawing on proprietary interviews with operators and deep, validated intelligence on over 12 million companies. It gives decision-makers an edge by enriching their AI agents with expert judgment, nonpublic signals, and a complete map of technology markets. Six of the Mag 7 and the top 10 U.S. banks rely on CB Insights to build conviction in their next investment, acquisition, partner, or customer. Learn more at www.cbinsights.com.

About Galux

Galux is an AI biotechnology company developing precision protein design technology for next-generation therapeutics. Its proprietary platform, GaluxDesign, combines AI with atomic-level physical and chemical principles to design novel antibodies and other therapeutic proteins de novo with desired properties.

Galux applies its technology to challenging therapeutic targets and differentiated modalities through collaborations with global pharmaceutical companies and its own therapeutic pipeline, with a focus on translating AI-designed molecules into new medicines. For more information, visit galux.co.kr.

Media gallery